Durrant says the now ongoing trial is the first randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of an anti-GM-CSF conducted in the US.
Humanigen achieves significant milestone in dosing first coronavirus patient in Phase 3 trial
Quick facts: Humanigen, Inc.
Price: - -
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE